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AbstrAct
Objectives To assess the longitudinal evidence of the 
relationships between sleep disturbances (of quantity and 
quality) and dyslipidaemia in the general population and to 
quantify such relationships.
setting Systematic review and meta-analysis following 
the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses guidelines.
Methods We performed a systematic search of PubMed 
and Embase (up to 9 September 2017), complemented 
with manual searches, of prospective population studies 
describing the association between sleep duration and 
quality and the incidence of dyslipidaemias. Relative risks 
(95% CIs) were extracted and pooled using a random 
effects model. Subgroup analyses by lipid type were 
performed. Heterogeneity and publication bias were also 
assessed. Quality was assessed with Downs and Black 
score.
Participants Studies were included if they were 
prospective, had measured sleep quantity and/or quality 
at baseline and either incident cases of dyslipidaemia or 
changes in blood lipid fractions assessed prospectively.
Primary outcome measures Incidence of dyslipidaemia 
and changes in lipid fractions. Dyslipidaemia was defined 
as a high total cholesterol, triglycerides, low-density 
lipoprotein cholesterol or low high-density lipoprotein 
cholesterol compared with the reference group.
results Thirteen studies were identified (eight using 
sleep duration, four sleep quality and one both). There 
was heterogeneity in the sleep quality aspects and types 
of lipids assessed. Classification of sleep duration (per 
hour/groups) also varied widely. In the pooled analysis 
of sleep duration (6 studies, 16 cohort samples; 30 033 
participants; follow-up 2.6–10 years), short sleep was 
associated with a risk of 1.01 (95% CI 0.93 to 1.10) of 
developing dyslipidaemia, with moderate heterogeneity 
(I2=56%, P=0.003) and publication bias (P=0.035). Long 
sleep was associated with a risk of 0.98 (95% CI 0.87 
to 1.10) for dyslipidaemia, with heterogeneity (I2=63%, 
P<0.001) and no significant publication bias (P=0.248).
conclusion The present analysis was unable to find 
supportive evidence of a significant relationship between 
sleep duration and the development of dyslipidaemia. 
However, heterogeneity and small number of studies limit 
the interpretation.
PrOsPErO registration number CRD42016045242.
bAckgrOund
Research into sleep and its effects on health 
has increased in recent years. This has been 
accompanied by public health concerns 
about the declining quality and quantity of 
sleep in modern society.1 Both short and long 
sleep duration are consistently associated with 
mortality and serious chronic diseases, such as 
diabetes and cardiovascular disease (CVD).2–4 
Similarly, poor sleep quality has been associ-
ated with mortality and CVD.4 5 CVD is the 
leading cause of non-communicable disease 
deaths globally and deaths by CVD have risen 
by 12.5% between 2005 and 2015.6 There is 
still debate about whether the association 
between sleep and CVD is causal or whether 
sleep disturbances are merely symptoms or 
risk markers of disease.7 Understanding the 
possible mechanisms through which sleep 
affects CVD can provide important supportive 
evidence for a causative link.
U-shaped relationships between duration 
of sleep and risk factors for CVD, such as 
hypertension and metabolic syndrome have 
been observed.8 9 For obesity, the longitu-
dinal association is most clear in paediatric 
populations, in which shorter sleep is associ-
ated with an increased risk of obesity.10 Fewer 
studies have been performed on sleep quality, 
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Research
strengths and limitations of this study
 ► This is the first study evaluating the collective 
prospective evidence of the association between 
sleep duration and biomarkers of lipid metabolism.
 ► Strengths of this review include the broad search 
strategy and in-depth quality assessment of studies.
 ► Limitations to interpretation are: heterogeneity of 
exposure and outcome measurements  and small 
number of studies.
 ► The results can only be representative of published 
and included studies.
group.bmj.com on March 23, 2018 - Published by http://bmjopen.bmj.com/Downloaded from 
2 Kruisbrink M, et al. BMJ Open 2017;7:e018585. doi:10.1136/bmjopen-2017-018585
Open Access 
Figure 1 PRISMA flow diagram of study selection. HDL, high-density lipoprotein; LDL, low-density lipoprotein; PRISMA, 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses; TC, total cholesterol; TG, triglyceride.
but poor sleep quality has also been associated with an 
increased risk of hypertension,11 metabolic syndrome12 
and diabetes.2
An unfavourable blood lipid profile, including high 
total cholesterol (TC) and low-density lipoprotein choles-
terol (LDL-C), is a well-established risk factor for CVD.13 
Circulating lipids are influenced by lifestyle factors such 
as diet, smoking and physical activity.14 Whether sleep 
duration and quality are associated with blood lipids 
remains to be ascertained.
Systematic reviews of observational studies suggest 
a lack of consistency in the association between sleep 
duration and lipid profiles, with a large heterogeneity 
in the classification of exposure and outcome and the 
type of analysis. Furthermore, these were mainly based 
on cross-sectional evidence—hence unable to establish a 
temporal relationship between exposure and outcome—
and did not evaluate sleep quality as a potential exposure 
of interest.15 16 In recent years, new prospective studies 
that include measures on sleep and blood lipids have 
emerged. Nadeem et al17 performed a meta-analysis of 64 
observational studies involving 18 116 patients on obstruc-
tive sleep apnoea (OSA) and the blood lipid profile. They 
found that OSA was associated with a significantly higher 
risk of dyslipidaemia, for example, high TC and LDL-C, 
high triglyceride (TG) and low high-density lipoprotein 
cholesterol (HDL-C). However, this meta-analysis was 
performed in a specific patient group, did not include 
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sleep duration as an exposure and was based on cross-sec-
tional studies.
To the best of our knowledge, a meta-analysis of 
prospective studies on sleep quality and duration, and 
blood lipids in the general population without diagnosed 
sleep disorders has not yet been published. We set out to 
systematically evaluate prospective studies for an associa-
tion between sleep duration and quality, and blood lipids 
in the general population and to pool the evidence in a 
meta-analysis.
dAtA And MEthOds
This systematic review and meta-analysis was conducted 
according to the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) guidelines.18 
PROSPERO registration number: CRD42016045242, 
available from  http://www. crd. york. ac. uk/ PROSPERO/ 
display_ record. asp? ID= CRD42016045242.
search strategy
The electronic databases, PubMed (from 1996) and 
EMBASE (from 1947), were searched on 9 September 
2017 using keywords related to exposure (sleep duration 
and quality), outcome (blood lipids) and design (prospec-
tive). Abbreviations, plural forms and alternate spellings 
(American-English) of keywords were searched. The 
search was restricted to human research and published 
journal articles. No language restriction was applied. In 
addition, a manual check of reference lists was performed 
using (1) previous review articles on the subject, (2) rele-
vant review articles identified in the search and (3) arti-
cles included in the present study. Additional searches 
were performed into the studies that measured lipids at 
baseline and follow-up, but did not report on lipids, to see 
if additional publications were available which did report 
on the outcome of interest.
study selection
After title and abstract scanning, full-text articles were 
retrieved. Prospective articles were evaluated for inclu-
sion by two of three investigators (MK, WR and FPC) 
according to the following criteria set a priori: (A) original 
published article, (B) observational prospective design, 
(C) a baseline assessment of exposures (sleep duration 
or sleep quality) and (D) one of the following outcomes: 
(1) a change in serum lipids over time or (2) a relative 
risk of developing dyslipidaemia in short or long sleepers 
compared with the reference sleep category. Studies were 
excluded if (A) exposure was napping or shift work, (B) 
population had a diagnosed sleep disorder like OSAS 
or pre-existing cardiovascular or metabolic disease, (C) 
it was a case–control study. No sample size, age or dura-
tion of follow-up restriction was applied. Disagreement 
on inclusion was resolved by discussion and consensus 
among the three investigators. Authors were contacted 
for additional data.
data extraction
Data from each study was extracted independently by two 
investigators (MK and FPC). Extracted data included: 
first author, year of publication, country of origin of the 
population, recruitment year of cohort, age (at sleep 
assessment), sex, duration of follow-up, number of partic-
ipants included, methods of assessment of both exposure 
and outcome, definitions of sleep categories, relative risks 
(RR), HR, OR, regression coefficients (β) representing 
changes in lipid levels, 95% CI, SE and adjustment for 
covariates. SEs were derived from CI if not reported 
(online supplementary appendix table A1). The most 
adjusted estimates were used for analysis. When data 
were reported for men and women separately, they were 
entered for analysis as two separate cohorts. When data 
from the same cohort was published in separate papers, 
only one estimate was used (usually the longer follow-up 
or the largest dataset). Differences in extracted informa-
tion were resolved by discussion and consensus among 
two of the investigators.
risk of bias assessment
The quality of the included studies was assessed using the 
Downs and Black Quality Index Score.19 This checklist 
includes items for measuring a study’s reporting quality, 
external validity, bias, confounding and power. The 
maximum score for prospective studies is 20.
statistical analysis
A random effects model with inverse-variance weighting 
was used to pool HRs, ORs and RRs into RRs for devel-
oping high TC, low HDL-C, TC/HDL-C ratio ≥5 and high 
TG in short sleepers and long sleepers compared with the 
reference category. Ratio measures and standard errors 
were transformed into natural logarithms for analysis. For 
a detailed overview and examples of data transformations 
performed, see online supplementary appendix table 
A2. Changes in lipid levels over time were meta-analysed 
using a random effects model when at least two cohorts 
with a similar exposure and outcome measurement were 
available. Due to heterogeneity in sleep quality aspects 
and types of outcomes reported, we were unable to meta-
analyse the studies on sleep quality. Publication bias was 
assessed with examination of funnel plot symmetry and 
Egger’s regression test for small study effects when the 
number of cohorts available was greater than 2. Hetero-
geneity was investigated with Q test statistic and quan-
tified by I2 statistics. The following thresholds for I2 
interpretation from Cochrane Reviews were used: ‘0% to 
40%: might not be important; 30% to 60%: may repre-
sent moderate heterogeneity; 50% to 90%: may represent 
substantial heterogeneity; 75% to 100%: considerable 
heterogeneity’.20 The influence of individual studies was 
investigated by excluding one study at a time. A two-tailed 
P value <0.05 was considered statistically significant. Statis-
tical analyses were performed with Stata V.14 (StataCorp, 
College Station, Texas, USA).
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rEsults
Identified studies
Searches yielded 1594 titles (figure 1). After title and 
abstract scanning, 157 full-text articles were retrieved. 
Twelve studies were identified in the search, seven 
concerned only sleep duration, one concerned only sleep 
quality and one concerned both. Searching the refer-
ences of included studies yielded one additional study 
regarding sleep quality, yielding a total of 13 studies. Four 
authors were contacted21–24 for additional data of whom 
one could provide data.
Assessment and definition of exposures
Sleep duration was mostly self-reported, either by ques-
tionnaire21 24–28 or interview29 30 (table 1). Three studies 
used accelerometry to assess sleep duration.23 31 32 Sleep 
duration was analysed as a continuous measure in four 
studies, meaning a risk29 or change in lipid levels per 
hour of sleep increase23 31 32 was reported. Two studies 
used qualitative groups27 28 and five used sleep duration 
groups for analysis. Short sleep was defined as ≤6 hou
rs,21<5 hours,24<6 hours25 30 and <7 hours.26 Long sleep 
duration was defined as ≥9 hours,21 25 ≥7 hours24 and 
≥10 hours.26 33 Subjective aspects of sleep quality that have 
been evaluated by questionnaire include difficulty falling 
asleep,33 34 difficulty maintaining sleep,33 unrefreshing or 
non-restorative sleep,33 34 presence or absence of sleep 
disorder,28 frequency of sleep duration27 and Pittsburgh 
Sleep Quality Index (PSQI) score.23 Sleep fragmentation 
was objectively assessed with accelerometry in one study.23
change from protocol
In the original protocol submission to PROSPERO 
(CRD42016045242), the Outcome(s) section reads 
Primary outcomes: we expect most studies will have 
measured cholesterol. The expected primary outcomes are 
therefore changes in TC or the risk of developing hyper-
cholesterolaemia. Secondary outcomes: the following 
outcomes will also be assessed: changes in serum levels 
HDL-C, LDL-C and TGs and the risk of developing dyslip-
idaemia (this can be hypercholesterolaemia, hypertri-
glyceridaemia, etc). The submission reflects the ‘a priori’ 
uncertainty on how the outcomes in prospective studies 
would look like. After the search, it became apparent that 
the most common form of outcome in prospective studies 
was indeed ‘incidence of dyslipidaemia’. We report all 
outcomes originally planned to avoid the risk of selective 
outcome reporting.
Assessment and definition of outcome
For an overview of outcomes assessed, see table 1. 
To assess outcomes, 10 studies used a fasting blood 
samples,21 23–27 30–32 2 self-report28 29 and 1 data register.34 
TC was assessed in six studies,23 24 26 27 29 32 HDL-C in seven 
studies,23–26 30 31 33 LDL-C in three studies,23 24 26 TG in eight 
studies,21 23–26 30 31 33 non-HDL-C in one study24 and TC/
HDL-C ratio in one study.23 One study assessed changes in 
lipid levels,31 10 studies reported a risk of dyslipidaemia 
for one or more lipids or lipid fractions21 24 25 27–33 and 
1 study reported on both.23 Furthermore, one study 
assessed changes in lipid levels compared with a refer-
ence group.26 Dyslipidaemia was defined as a high TC, 
TG, LDL-C or low HDL-C compared with the reference 
group as described in table 1.
study characteristics
All identified publications were recent (2010–
2017) (table 1). Ten studies were performed in 
adults,21 23–28 30 33 34 one in adolescents29 32 and one in chil-
dren.31 Twelve studies recruited men and women,21 23 25–34 
four of these reported on outcomes in men and women 
separately.23 25 29 32 34 One study recruited only men.24 
Follow-up ranged from 200 days to >20 years. Four studies 
were performed in the USA,23 29 32 33 two in China25 26 
and Finland,32 34 one in Canada,21 Denmark31, France,28 
Japan24 and South Korea.30
sleep quality
In online supplementary appendix table A3, an overview 
of the results reported in the individual studies for sleep 
quality is given. In general, studies reported both favour-
able and unfavourable associations of poor sleep quality 
with blood lipids. The associations reported differed 
by lipid type and aspects of sleep quality assessed. Only 
Haaramo et al34 reported significant associations. Those 
occasionally or frequently suffering from insomnia symp-
toms had a significantly increased risk of dyslipidaemia 
medication compared with those without insomnia 
symptoms.
sleep duration and dyslipidaemia risk
The quality of studies included in the meta-analyses ranged 
from 12 to 18 out of a maximum score of 20 (see online 
supplementary appendix table A4). All studies scored 
high on items of reporting and bias. Studies scored less 
well on items of external validity and confounding. All 
studies lacked in adequate confounder adjustment by not 
adjusting for at least one of the following factors: base-
line lipid levels, dyslipidaemia medication, other sleep 
variables or depression. Meta-analyses included three 
cohorts with high TC (21 453 participants), four cohorts 
with low HDL-C (11 851 participants), two cohorts with 
high TC/HDL-C ratio (503 participants) and five cohorts 
with high TG (11 450 participants). Meta-analyses of short 
sleep duration by different lipids fractions are shown 
in figure 2. In an overall pooled analysis of sleep dura-
tion (6 studies, 16 cohort samples; 30 033 participants; 
follow-up 2.6–10 years), short sleep was associated with 
a risk of 1.01 (95% CI 0.93 to 1.10) of developing any 
dyslipidaemia, with moderate heterogeneity (I2=56%, 
P=0.003) and publication bias (P=0.035). Short sleep was 
associated with a non-significant increased risk of devel-
oping high TC (RR=1.10; 95% CI 0.99 to 1.22; P=0.07; 
no heterogeneity and publication bias). There were not 
enough observations to perform an Egger’s test for the 
risk of TC/HDL-C ratio ≥5, there was no evidence for 
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publication bias for the remaining lipid types (see online 
supplementary appendix figures A1 a–c).
Meta-analyses of long sleep duration by different lipid 
fractions are shown in figure 3. In an overall pooled anal-
ysis, the risk of any dyslipidaemia among long sleepers was 
0.98 (95% CI 0.87 to 1.10), with heterogeneity (I2=63%, 
P<0.001) and no significant publication bias (P=0.248). 
There were not enough observations to perform an 
Egger’s test for the risk of TC/HDL-C ratio≥5, there was 
no evidence for publication bias for the remaining lipid 
types (see online supplementary appendix figure A1 d-f).
sleep duration and lipid changes over time
There were too few studies to draw any meaningful 
conclusions from this analysis. (table 2). An increase in 
sleep duration was not associated with a change in HDL 
cholesterol. Furthermore, Yang et al32 report changes in 
lipid levels in short and long sleepers compared with 
a 7–8 hours reference group. None of these associa-
tions reached significance, except for an 0.085 mmol/L 
(95% CI 0.014–0.156, P unreported) increase in TG for 
those sleeping ≥10 hours compared with those sleeping 
7–<8 hours.
dIscussIOn
To our knowledge, this is the first systematic review and 
meta-analysis of the current prospective evidence on 
the relation between sleep quality, sleep duration and 
blood lipids in the general population. The results were 
not influenced by age, study quality, follow-up duration, 
gender or sleep assessment method. The analysis was 
carried out by separate lipid fractions. The risk of the 
development of dyslipidaemia varied among short and 
long sleepers and by lipid type.
Like Abreu et al,16 we found that studies often adjusted 
for factors such as diet and body mass index, without 
exploring potential mediation, while the influence of 
other sleep variables are ignored. Sleep disordered 
breathing was not taken into account in any of the 
included studies, even though it has been associated with 
an increased risk of dyslipidaemia.18 Another factor that 
was inconsistently taken into account was stress, which 
can be a determinant of both poor sleep and increased 
stress levels. In the Whitehall II study, cortisol secretion 
was raised in those reporting short sleep duration and 
high sleep disturbance.35
Polysomnography is the gold standard for objective 
assessment of sleep quality and quantity, but objective 
sleep assessment is often not feasible in large cohort 
studies. Sleep quality and quantity were assessed subjec-
tively by questionnaire or interview in most included 
studies. Moderate correlation between assessment of 
sleep duration by self-report and more objective actig-
raphy assessment have been observed in the Coronary 
Artery Risk Development in Young Adults study.36 Simi-
larly, the Pittsburgh Sleep Quality Index and Epworth 
Sleepiness scale, two often used subjective measures of 
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Figure 2 Forest plot of risk of dyslipidaemia in short sleepers. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride.
sleep quality, do not correlate well with objective sleep 
measures.37 In all included studies, a single measurement 
of sleep was taken at baseline, which may not represent 
the full sustained effect of sleep duration.
In previous systematic reviews, both long and short 
sleep duration were strongly associated with health 
outcomes, including cardiovascular disease.1 4 No such 
effects were found in this meta-analysis. It is possible that 
the effects of sleep duration on cardiovascular health are 
not mediated through blood lipids,38 but through other 
pathways such as obesity, hypertension and inflamma-
tion.10 39–41 However, an effect of sleep duration on blood 
lipids would be biologically plausible. Sleep restriction 
is associated with an altered secretion of metabolic and 
hunger hormones, such as growth hormone, cortisol, 
leptin and ghrelin.42–44 Furthermore, sleep can influ-
ence eating behaviour and physical activity. Short sleep 
time and non-restorative sleep have been associated with 
a dietary alterations reflecting a higher intake of energy 
and fat.45–47 Sleep loss has also been shown to decrease 
physical activity in free-living conditions,48 and insuffi-
cient sleep could undermine dietary efforts to reduce 
adiposity.49 Several short-term experimental studies 
also suggest an effect of sleep restriction on blood lipid 
levels.50 51 Since it is difficult to have people sleep for 
long periods of time, mechanisms for the effects of long 
sleep duration on health have been less investigated and 
remain mostly speculative. It is possible that the observed 
relationship between long sleep duration and cardiovas-
cular outcomes reflects long sleep duration being a risk 
marker or symptom of disease rather than a cause.7
strengths and limitations
Strengths of this review include the broad search strategy 
and in-depth quality assessment of studies. The high 
heterogeneity of exposure and outcome measurements 
encountered in this review limited the scope of the 
meta-analysis. We were unable to perform a meta-analysis 
for sleep quality. The results can only be representative of 
published and included studies and the interpretation is 
limited by the small number of studies and some publica-
tion bias. Other limitations include the inability to directly 
adjust for confounding with study level meta-analysis and 
the fact that the quality of the meta-analysis cannot go 
beyond the quality of the included studies.
Perspectives
We do not yet have the strength of evidence needed to 
inform public health policy on the relation between sleep 
quality and duration and blood lipid profiles. In future 
research, individual patient data meta-analysis could 
provide possibilities to analyse data in a more homoge-
neous way. Furthermore, this review and meta-analysis 
focused on the general healthy population only. There 
are indications for an association between sleep and blood 
lipids in patients with diabetes52 and mental illness.53 
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Figure 3 Forest plot of risk of dyslipidaemia in long sleepers. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density 
lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride.
Table 2 Meta-analytical results for continuous outcomes
Blood lipid 
fraction
No of 
studies 
and 
cohorts n
Publication 
bias
Change in lipid 
levels per hour 
of sleep
Total 
cholesterol
One 
study, 
two 
cohorts
503 — 0.14 (0.06 to 
0.23), P=0.001, 
I2=0.0
HDL 
cholesterol
Two 
studies, 
three 
cohorts
989 P=0.020 0.00 (−0.02 to 
0.03), 
P=0.719, 
I2=0.0
LDL 
cholesterol
One 
study, 
two 
cohorts
503 — 0.09 (0.01 to 
0.17), 
P=0.033, 
I2=0.0
Triglycerides Two 
studies, 
three 
cohorts
989 P=0.450 0.01 (0.01 to 
0.01), 
P<0.001, 
I2=0.0
Values are reported in millimole per litre with 95% CI.
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Other potential areas for future research are sleep timing 
and circadian disruption. Cross-sectional evidence indi-
cates sleep timing and patterns may be associated with 
unfavourable lipid profiles,54 although causality cannot 
be implied from those studies. Disruptions in the circa-
dian rhythm have also been shown to be associated with 
metabolic alterations.55 Sleep disturbances are important 
to consider in the light of other CVD risk factors, such 
as obesity, hypertension and diabetes. randomised 
controlled trials that evaluate the effect of improved 
sleep habits on obesity and cardiovascular health are now 
becoming available.56–58
cOnclusIOn
The present analysis was unable to find supportive 
evidence of a relationship between sleep duration and 
the development of dyslipidaemia. However, heteroge-
neity and small number of studies limit the interpreta-
tion. Further prospective studies are needed.
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